NEW YORK--(BUSINESS WIRE)--Viriathus Research LLC, an independent research firm, issued an Overview Report today on Benitec Limited (ASX: BLT), Benitec was formed to commercialize applications for RNA interference (RNAi) technology in treating chronic and life-threatening human conditions.
Benitec’s dominant worldwide intellectual property position in the application of its RNAi technology for human therapeutics has been confirmed following the re-issue of the ‘099 Graham patent. The Company holds numerous worldwide patents and licenses for a transformational platform technology called DNA-directed RNA interference or ddRNAi, which harnesses the body’s own defense mechanisms to silence the expression of condition-associated genes, thus paving the way for new breakthrough medical treatments.
The Overview Report provides a description of Benitec’s business, industry, product, strategy, management team and investment opportunities and risks.
Benitec is headquartered in Melbourne, Australia and trades on the Australian stock exchange under the symbol “BLT”. The Company was founded in 1997 and has been publicly held since 2001.
A complimentary copy of this report is available for download from Benitec or Viriathus' website at: http://www.benitec.com or http://www.viriathus.com.
About Viriathus Research LLC
Viriathus Research is a quality-leading New York based independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutional investors that invest in them. For further information on Viriathus Research please visit http://www.viriathus.com.
About Benitec Limited
Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology’s potential to address unmet medical needs and, potentially, to cure disease results from the demonstrated ability to permanently silence genes which cause the condition. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.
Statement under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.
Viriathus Research was compensated US$25,000.00 for the authoring of this report.